Forced expiratory volume in 1 second percentage improves the classification of severity among children with asthma

Pediatrics

Volumn 118, Issue 2, 2006, Pages

  Fuhlbrigge, Anne L ^a,d   Weiss, Scott T ^a   Kuntz, Karen M ^b   Paltiel, A David ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CHANNING LABORATORY   (United States)

Author keywords

Asthma; Severity classification; Spirometry; Treatment outcome

Indexed keywords

BUDESONIDE; CORTICOSTEROID; NEDOCROMIL; PLACEBO; SALBUTAMOL; ANTIASTHMATIC AGENT; BRONCHODILATING AGENT; DIAGNOSTIC AGENT; METHACHOLINE CHLORIDE;

ARTICLE; ASTHMA; BRONCHODILATATION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SPIROMETRY; CLASSIFICATION; COHORT ANALYSIS; EMERGENCY HEALTH SERVICE; ETHNIC GROUP; INHALATION TEST; PATHOPHYSIOLOGY; PRESCHOOL CHILD; RISK; STATISTICS; THEORETICAL MODEL; TREATMENT OUTCOME; UTILIZATION REVIEW;

ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHIAL PROVOCATION TESTS; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DOUBLE-BLIND METHOD; EMERGENCY SERVICE, HOSPITAL; ETHNIC GROUPS; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMANS; MALE; METHACHOLINE CHLORIDE; MODELS, THEORETICAL; MULTICENTER STUDIES; NEDOCROMIL; RANDOMIZED CONTROLLED TRIALS; RISK; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TREATMENT OUTCOME;

EID: 33748422389     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-2962     Document Type: Article

References (33)

1. Hewson PH, Tippett EA, Jones DM, Maddern JP, Higgs P. Routine pulmonary function tests in young adolescents with asthma in general practice. Med J Aust. 1996;165:469-472
2. Ferguson GT, Enright PL, Buist AS, Higgins MW. Office spirometry for lung health assessment in adults: a consensus statement from the National Lung Health Education Program. Chest. 2000;117:1146-1161
3. Celli BR. The importance of spirometry in COPD and asthma: effect on approach to management. Chest. 2000;177(suppl):15S-19S
4. Irvin CG. To blow or not to blow - that is the question. Respir Care. 2002;47:1145-1147
5. National Asthma Education and Prevention Program Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health; 1997. Publication 97-4051
6. Enright PL, Lebowitz MD, Cockroft DW. Physiologic measures: pulmonary function tests. Asthma outcomes. Am J Respir Crit Care Med. 1994;149(pt 2):S9-S18; discussion S19-S20
7. Enright PL, Johnson LR, Connett JE, Voelker H, Buist AS. Spirometry in the Lung Health Study. 1. Methods and quality control. Am Rev Respir Dis. 1991;143:1215-1223
8. Fuhlbrigge AL, Carey VJ, Lozano P, et al. Performance characteristics of pediatric asthma symptom reports for outcomes research [abstract]. Am J Respir Crit Care Med. 2001;163:A316
9. Kitch BT, Patiel AD, Kuntz KM, et al. A single measure of FEV(1) is associated with risk of asthma attacks in long-term fellow-up. Chest. 2004;126:1875-1882.
10. Fuhlbrigge AL, Kitch BT, Paltiel AD, et al. FEV(1) is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol. 2001;107:61-67
11. Kitch BT, Paltiel AD, Kuntz KM, et al. A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest. 2004;126:1875-1882
12. Childhood Asthma Management Program Research Group. The Childhood Asthma Management Program (CAMP): design, rationale, and methods. Control Clin Trials. 1999;20:91-120
13. Coultas DB, Howard CA, Skipper BJ, Samet JM. Spirometric prediction equations for Hispanic children and adults in New Mexico. Am Rev Respir Dis. 1988;138:1386-1392
14. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis. 1983;127:725-734
15. Finkelstein JA, Lozano P, Shulruff R, et al. Self-reported physician practices for children with asthma: are national guidelines followed? Pediatrics. 2000;106(suppl):886-896
16. Doerschug KC, Peterson MW, Dayton CS, Kline JN. Asthma guidelines: an assessment of physician understanding and practice. Am J Respir Crit Care Med. 1999;159:1735-1741
17. Collins S, Beilby J, Fardy J, Burgess T, Johns R, Booth B. The national asthma audit. Bridging the gap between guidelines and practice. Aust Fam Physician. 1998;27:907-913
18. Pearson MG. How can the implementation of guidelines be improved? Chest. 2000;117(suppl):38S-41S
19. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282:1458-1465
20. Grant EN, Moy JN, Turner-Roan K, Daugherty SR, Weiss KB. Asthma care practices, perceptions, and beliefs of Chicago-area primary-care physicians. Chicago Asthma Surveillance Initiative Project Team. Chest. 1999;116(suppl 1):145S-154S
21. Picken HA, Greenfield S, Teres D, Hirway PS, Landis JN. Effect of local standards on the implementation of national guidelines for asthma: primary care agreement with national asthma guidelines. J Gen Intern Med. 1998;13:659-663
22. Noonan M, Chervinsky P, Busse WW, et al. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med. 1995;152:1467-1473
23. Corren J, Harris A, Fourre J. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol. 1997;100:781-788
24. Okamoto LJ, Noonan M, DeBoisblanc BP, Kellerman DJ. Fluticasone propionate improves quality of life in patients with asthma requiring oral corticosteroids. Ann Allergy Asthma Immunol. 1996;76:455-461
25. Agertoft L, Pedersen S. Effects of long term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med. 1994;88:373-381
26. Dzyngel B, Kesten S, Chapman KR. Assessment of an ambulatory care asthma program. J Asthma. 1994;31:291-300
27. Ogirala RG, Sturm TM, Aldrich TK, Meller FF, Pacia EB, Keane AM. Single, high dose intramuscular triamcinolone acetonide versus weekly oral methotrexate in life threatening asthma: a double blind study. Am J Respir Crit Care Med. 1995;152:1461-1466
28. Tamaoki J, Kondo M, Sakai N, Nakata J, Takemura H, Nagai A. Leukotriene antagonist prevents exacerbation of asthma during reduction of high dose inhaled corticosteroid. The Tokyo Joshi Idai Asthma Research Group. Am J Respir Crit Care Med. 1997;155:1235-1240
29. Braun-Fahrlander C, Gassner M, Grize L, Minder CE, Varonier HS, Vuille JC. Comparison of responses to an asthma symptom questionnaire (ISAAC) completed by adolescents and their parents. Pediatr Pulmonol. 1998;25:159-166
30. Strunk RC, Sternberg AL, Bacharier LB, Szefler SJ. Nocturnal awakening caused by asthma in children with mild-to-moderate asthma in the childhood asthma management program. J Allergy Clin Immun. 2002;110:395-403
31. Li D, German D, Lulla S, Thomas RG, Wilson SR. Prospective study of hospitalization for asthma. Am J Respir Crit Care Med. 1995;151:647-655
32. Lieu TA, Quesenberry CP, Sorel ME, Mendoza GR, Leong AB. Computer-based models to identify high-risk children with asthma. Am J Respir Crit Care Med. 1998;157(pt 1):1173-1180
33. Bacharier LB, Dawson C, Bloomberg C, Bender B, Wilson L, Strunk RC. Hospitalization for Asthma: atopic, pulmonary function, and psychological correlates among participants in the Childhood Asthma Management Program. Pediatrics. 2003;112(2). Available at: www.pediatrics.org/cgi/content/ full/112/2/e85